Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
S1P Asset Will Add To JAK-Heavy Pipeline
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
